<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00284947</url>
  </required_header>
  <id_info>
    <org_study_id>CCHI621A2402</org_study_id>
    <nct_id>NCT00284947</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids</brief_title>
  <official_title>REPLACE: Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-term use of calcineurin inhibitors (CNI) in patients who have received a kidney
      transplantation is associated with renal dysfunction and hypertension. The study will
      evaluate the safety and efficacy of replacing the calcineurin inhibitors by using basiliximab
      at monthly doses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to describe the pharmacokinetics of basiliximab over the 6-month study course and to determine whether serum concentrations remain above CD25 receptor saturation levels</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to evaluate the risk of sensitization against the chimeric antibody over 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess the changes in renal parameters after CNI discontinuation</measure>
    <time_frame>Month 1-6 post trasnplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess the quantifiable changes in vital signs and lab abnormalities possibly related to CNIs</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess semi-quantitatively changes of clinical symptoms possibly related to CNIs</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the percentage of CD25 positive T cells (CD3) during therapy with Simulect</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Adverse Effects</condition>
  <arm_group>
    <arm_group_label>Maintenance immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg Simulect i.v, once every 28 days for 24 weeks (treatment periods)
1g MMF or 720mg EC-MPS p.o twice daily
Oral corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>basiliximab</intervention_name>
    <description>40 mg once every 28 days intravenously for 24 weeks</description>
    <arm_group_label>Maintenance immunosuppression</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF/EC-MPS</intervention_name>
    <description>1g MMF or 720mg EC-MPS p.o twice daily</description>
    <arm_group_label>Maintenance immunosuppression</arm_group_label>
    <other_name>MPA</other_name>
    <other_name>Myfortic</other_name>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days</description>
    <arm_group_label>Maintenance immunosuppression</arm_group_label>
    <other_name>Prednisone</other_name>
    <other_name>Methyl-prednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a first kidney transplant from a living or deceased donor at least 12
             months after transplantation.

          -  Patients receiving CNI, mycophenolic acid (MPA) and oral corticosteroids.

          -  Patients who are able to tolerate full dose MPA.

          -  Patients with glomerular filtration rate (GFR) &gt; 30 mL/min.

          -  Patients without an acute rejection episode during the preceding 6 months.

          -  Patients with signs or symptoms of CNI intolerance (renal dysfunction, poor blood
             pressure control, diabetes, poor lipid control, hyperuricemia and gout, significant
             hypophosphatemia or hypomagnesemia, gingival hyperplasia, hypertrichosis, etc.) in
             whom CNI interruption is justified.

        Exclusion Criteria:

          -  Patients with preformed positive skin test against basiliximab

          -  Patients with preformed panel reactive antibody (PRA) &gt; 10%.

          -  Signs of active immune process on graft biopsy.

          -  Patients with multi-organ or second kidney transplant

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2845</url>
    <description>Results for CCHI621A2402 from the Novartis Clinical Trials website.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2006</study_first_submitted>
  <study_first_submitted_qc>January 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Side effects</keyword>
  <keyword>calcineurin inhibitors</keyword>
  <keyword>maintenance</keyword>
  <keyword>basiliximab</keyword>
  <keyword>Kidney maintenance transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

